Prognia
Drug Database
🇪🇺EU · EMAApplication withdrawnATC: LX1XX02Orphan Medicine

Graspa(asparaginase)

Precursor Cell Lymphoblastic Leukemia-Lymphoma

Marketing Authorisation Holder: ERYTECH Pharma S.A.

EMA Authorisation: 27/06/2018

INN: asparaginase

Indication

Treatment of acute lymphoblastic leukaemia

Official EMA Resources

View on EMA (ema.europa.eu)

AI Drug & Interaction Analysis

Free account required

Ask Prognia AI about Graspa — dosing recommendations, drug interactions, and current guideline evidence from ESC, EMA, NICE and more.

Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.